Testing effectiveness (Phase 2)Active Not RecruitingNCT05172258
What this trial is testing
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
Who this might be right for
Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaMetastatic Hypopharyngeal Squamous Cell Carcinoma+12 more
National Cancer Institute (NCI) 52